泰林生物
(300813)
| 流通市值：18.51亿 | | | 总市值：26.35亿 |
| 流通股本：8512.61万 | | | 总股本：1.21亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 165,382,315.28 | 70,063,538.95 | 339,538,843.84 | 213,188,852.61 |
| 营业总成本 | 148,978,158 | 66,596,113.34 | 329,644,577.8 | 201,314,970.5 |
| 其他经营收益 | | | | |
| 营业利润 | 21,872,211.34 | 5,374,760.91 | 16,938,093.32 | 15,621,995.66 |
| 利润总额 | 21,609,388.01 | 5,282,600.1 | 16,738,716.51 | 15,075,607.94 |
| 净利润 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 | 14,523,036.61 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 20,372,823.69 | 4,840,310.83 | 16,286,074.7 | 14,523,036.61 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 523,518,661.87 | 552,049,147.55 | 549,849,767.91 | 545,192,536.68 |
| 非流动资产: | | | | |
| 非流动资产合计 | 414,245,987.13 | 394,858,195.29 | 409,122,815.48 | 388,871,229.26 |
| 资产总计 | 937,764,649 | 946,907,342.84 | 958,972,583.39 | 934,063,765.94 |
| 流动负债: | | | | |
| 流动负债合计 | 144,855,136.28 | 137,913,485.1 | 152,135,819.45 | 140,694,036.14 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,184,366.92 | 2,545,336.65 | 2,545,336.65 | 3,225,150.58 |
| 负债合计 | 147,039,503.2 | 140,458,821.75 | 154,681,156.1 | 143,919,186.72 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 | 790,144,579.22 |
| 股东权益合计 | 790,725,145.8 | 806,448,521.09 | 804,291,427.29 | 790,144,579.22 |
| 负债和股东权益合计 | 937,764,649 | 946,907,342.84 | 958,972,583.39 | 934,063,765.94 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 201,678,247.37 | 88,775,297.84 | 355,762,860.49 | 255,549,763.42 |
| 经营活动现金流出小计 | 180,577,677.89 | 92,332,308.73 | 308,040,851.05 | 240,690,607.43 |
| 经营活动产生的现金流量净额 | 21,100,569.48 | -3,557,010.89 | 47,722,009.44 | 14,859,155.99 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 817,940,739.86 | 361,909,860.58 | 1,250,388,212.49 | 763,283,824 |
| 投资活动现金流出小计 | 726,382,304.26 | 291,774,544.5 | 1,247,985,597.33 | 744,686,237.12 |
| 投资活动产生的现金流量净额 | 91,558,435.6 | 70,135,316.08 | 2,402,615.16 | 18,597,586.88 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 11,174,000 | 11,174,000 |
| 筹资活动现金流出小计 | 35,885,014.98 | 47,169.81 | 51,898,869.94 | 51,558,964.1 |
| 筹资活动产生的现金流量净额 | -35,885,014.98 | -47,169.81 | -40,724,869.94 | -40,384,964.1 |
| 汇率变动对现金及现金等价物的影响 | -455,933.89 | -422,963.92 | -732,533.59 | -375,657.52 |
| 现金及现金等价物净增加额 | 76,318,056.21 | 66,108,171.46 | 8,667,221.07 | -7,303,878.75 |
| 期末现金及现金等价物余额 | 154,863,359.74 | 144,653,474.99 | 78,545,303.53 | 62,574,203.71 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 76,318,056.21 | - | 8,667,221.07 | - |